Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease
TED
1 other identifier
observational
80
1 country
1
Brief Summary
Graves' orbitopathy (GO) affects about 50% of patients with Graves' disease (GD), and some cannot be cured by current treatments. Orbital fibroblasts involves in the pathogenesis of GO by producing glycosaminoglycans and inflammatory cytokines. Since fibroblast growth factors (FGFs) binding to FGF receptors (FGFRs) can induce proliferation and differentiation of fibroblasts, investigators would like to measure the expression of FGFs and FGFRs in GO patients to see if inhibition of FGF-FGFR pathway has potential in treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 25, 2014
CompletedFirst Submitted
Initial submission to the registry
October 16, 2017
CompletedFirst Posted
Study publicly available on registry
October 27, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 25, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 25, 2020
CompletedOctober 31, 2017
October 1, 2017
3 years
October 16, 2017
October 29, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Serum concentration of selected growth factors
Investigators would like to measure fibroblast growth factors concentration (ug/mL) by ELISA according to the manufacturers' instruction
1 year
Secondary Outcomes (2)
RNA expression level of selected growth factor receptors
1 year
RNA expression level of selected growth factor receptors
1 year
Eligibility Criteria
Patients with thyroid eye disease
You may qualify if:
- diagnosed as thyroid eye disease
- suggested to accept orbital decompression
You may not qualify if:
- age below 20 or above 80
- pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Taiwan University Hospital Taipei, Taiwan
Taipei, Taiwan
Related Publications (1)
Shih SR, Liao SL, Shih CW, Wei YH, Lu TX, Chou CH, Yen EY, Chang YC, Lin CC, Chi YC, Yang WS, Tsai FC. Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves' Orbitopathy. Ocul Immunol Inflamm. 2021 Jan 2;29(1):193-202. doi: 10.1080/09273948.2019.1672196. Epub 2019 Oct 28.
PMID: 31657648DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 16, 2017
First Posted
October 27, 2017
Study Start
December 25, 2014
Primary Completion
December 25, 2017
Study Completion
December 25, 2020
Last Updated
October 31, 2017
Record last verified: 2017-10